<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02985333</url>
  </required_header>
  <id_info>
    <org_study_id>MM-2014</org_study_id>
    <nct_id>NCT02985333</nct_id>
  </id_info>
  <brief_title>Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>Efficacy and Safety of Paclitaxel/Cyclophosphamide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple MyelomaRefractory</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of paclitaxel in combination&#xD;
      with cyclophosphamide and dexamethasone in chinese patients with relapsed/refractory multiple&#xD;
      myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment for relapsed/refractory multiple myeloma (MM)remains a crucial challenge.The&#xD;
      investigators have previously shown that the combination of paclitaxel and cyclophosphamide&#xD;
      acts synergistically to induce apoptosis of myeloma cells in vitro. Based on these&#xD;
      preclinical studies, the investigators initiated a phase II clinical trial of paclitaxel 175&#xD;
      mg/m(2) IV over 3 h d1 combined with cyclophosphamide 200 mg/m(2) IV over 30-60 min d1,3,5&#xD;
      and dexamethasone 20mg IV over 30-60 min d1-4 in patients with relapsed or refractory MM.&#xD;
      This regimen was administered every four weeks for a total of six cycles&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>30 months</time_frame>
    <description>ORR is defined as the proportion of patients with CR, nCR or partial response (PR) based on modified EBMT criteria per investigator assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>30 months</time_frame>
    <description>PFS, defined as time from first dose of study treatment to progression or death due to any cause, as assessed by investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>30 months</time_frame>
    <description>OS, defined as time from first dose of study treatment to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of combination therapy assessed using the National Cancer institute-Common Toxicology Criteria (NCI-CTC) grade scale for AEs and Lab assessments</measure>
    <time_frame>30 months</time_frame>
    <description>Safety of combination therapy as assessed by toxicity, which will be assessed using the National Cancer Institute-Common Toxicology Criteria (NCI-CTC) grading scale for Adverse Events and for laboratory assessments (v4.03) that include biochemistry, hematology, urinalysis; special safety assessments that include LVEF, Thyroid function Creatinine clearance and ECGs (electrocardiograms).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Relapse/Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>paclitaxel 175 mg/m(2) IV over 3 h d1,cyclophosphamide 200 mg/m(2) IV d1,3,5 and dexamethasone 20mg IV d1-4 in patients with relapsed or refractory MM.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel 170 mg/m(2) IV over 3 h d1</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 200mgmg/m(2) IV d1,3,5</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 20mg iv d1-4</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>hexadecadrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has a previous diagnosis of multiple myeloma&#xD;
&#xD;
          -  Patient requires retreatment for multiple myeloma&#xD;
&#xD;
          -  Subject has measurable disease as defined by &gt; 0.5 g/dL serum monoclonal protein, &gt;10&#xD;
             mg/dL involved serum free light chain (either kappa or lambda) provided that the serum&#xD;
             free light chain ratio is abnormal, &gt;0.2 g/24 hrs urinary M-protein excretion, and/or&#xD;
             measurable plasmacytoma(s) of at least 1cm in greatest dimension as measured by either&#xD;
             CT scanning or MRI&#xD;
&#xD;
          -  Subject has a Karnofsky performance status ≥60% (&gt;50% if due to bony involvement of&#xD;
             myeloma (see Appendix IV)&#xD;
&#xD;
          -  Subject has a life expectancy ≥ 3 months&#xD;
&#xD;
          -  Subjects must meet the following laboratory parameters:&#xD;
&#xD;
        Absolute neutrophil count (ANC) ≥750 cells/mm3 (1.0 x 109/L) Hemoglobin ≥ 7 g/dL Platelet&#xD;
        count ≥ 75,000/mm3 (30 x 109/L if extensive bone marrow infiltration) Serum SGOT/AST &lt;3.0 x&#xD;
        upper limits of normal (ULN) Serum SGPT/ALT &lt;3.0 x upper limits of normal (ULN) Serum total&#xD;
        bilirubin &lt;2.0 mg/dL (34 µmol/L) Creatinine clearance ≥ 45 cc/min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has immeasurable MM (no measurable monoclonal protein, free light chains in&#xD;
             blood or urine, or measureable plasmacytoma on radiologic scanning)&#xD;
&#xD;
          -  Subject has a prior history of other malignancies unless disease-free for ≥ 5 years,&#xD;
             except for basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the&#xD;
             cervix or breast, or localized prostate cancer with Gleason score &lt; 7 with stable&#xD;
             prostate specific antigen (PSA) levels&#xD;
&#xD;
          -  Subject has had myocardial infarction within 6 months prior to enrollment, or NYHA&#xD;
             (New York Hospital Association) Class III or IV heart failure (see Appendix VI),&#xD;
             Ejection Fraction &lt; 35%, uncontrolled angina, severe uncontrolled ventricular&#xD;
             arrhythmias, electrocardiographic evidence of acute ischemia or active conduction&#xD;
             system abnormalities&#xD;
&#xD;
          -  Female subject who is pregnant or lactating&#xD;
&#xD;
          -  Subject has known HIV infection&#xD;
&#xD;
          -  Subject has known active hepatitis B or hepatitis C infection&#xD;
&#xD;
          -  Subject has active viral or bacterial infections or any coexisting medical problem&#xD;
             that would significantly increase the risks of this treatment program&#xD;
&#xD;
          -  Subject is unable to reliably take oral medications&#xD;
&#xD;
          -  Subject has known hypersensitivity to dexamethasone,cyclophosphamide,paclitaxel&#xD;
&#xD;
          -  Subject has a history of thromboembolic event within the past 4 weeks prior to&#xD;
             enrollment&#xD;
&#xD;
          -  Subject has any clinically significant medical or psychiatric disease or condition&#xD;
             that, in the investigator's opinion, may interfere with protocol adherence or a&#xD;
             subject's ability to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yue lu, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>hematological oncology department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>December 5, 2016</study_first_submitted>
  <study_first_submitted_qc>December 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2016</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>wanghua</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>paclitaxe,cyclophosphamide,dexamethasone, Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

